XNCRHealthcare · BiotechnologyThe 14 Wall Street analysts covering Xencor, Inc. hold a median 12-month price target of $27 — +39.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Xencor, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (82): The shares have been drifting up relative to others.
Revisions (40): Analysts have, on balance, been cutting their forecasts.
Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Xencor, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on XNCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +39.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | Wedbush | Reiterates | Outperform | $26 |
| 7 July 2026 | Truist Securities | Maintains | Buy | $29 → $27 |
| 7 July 2026 | Truist Securities | Maintains | Buy | — |
| 11 May 2026 | JP Morgan | Maintains | Neutral | — |
| 24 Mar 2026 | JP Morgan | Downgrade | Neutral | — |
| 26 Feb 2026 | Barclays | Maintains | Overweight | — |
| 17 Dec 2025 | Barclays | Maintains | Overweight | — |
| 24 Nov 2025 | Truist Securities | Initiates | Buy | — |
| 6 Nov 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 6 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 6 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 29 Oct 2025 | Barclays | Upgrade | Overweight | — |
| 27 Oct 2025 | RBC Capital | Maintains | Outperform | — |
| 6 Oct 2025 | Cantor Fitzgerald | Assumes | Overweight | $40 |
| 17 Sept 2025 | Barclays | Assumes | Underweight | $6.00 |
| 3 Sept 2025 | B of A Securities | Downgrade | Neutral | — |
| 2 Sept 2025 | Wedbush | Reiterates | Outperform | — |
| 21 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 7 Aug 2025 | Wedbush | Maintains | Outperform | — |
| 7 Aug 2025 | Wells Fargo | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 11% of US stocks
Cheaper than 42% of US stocks
Cheaper than 80% of US stocks
Higher than 2% of US stocks
Higher than 4% of US stocks
Higher than 5% of US stocks
Higher than 3% of US stocks
Higher than 27% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XNCR appears on the weeks it earns a place.
Xencor announced a Settlement Agreement with Alexion to resolve a commercial dispute related to U.S. royalties on Ultomoris (ravulizumab-cwvz). Under the agreement, Xencor will receive a payment from Alexion.
Why it matters — The resolution of this royalty dispute and the resulting payment provide clarity on a financial overhang for Xencor.
The 14 Wall Street analysts covering Xencor, Inc. have a median 12-month price target of $27, with estimates ranging from $14 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Xencor, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xencor, Inc. 72 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Xencor, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +39.2% from the last close, and Ticker Nerd's factor model ranks Xencor, Inc. 72 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Xencor, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XNCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $43 over the next 12 months.
Xencor, Inc. returned +143.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Xencor Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and antibody therapeutics.
The most recent item we track (Business Wire, 29 July 2026): "Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter". Xencor announced a Settlement Agreement with Alexion to resolve a commercial dispute related to U.S. royalties on Ultomoris (ravulizumab-cwvz). Under the agreement, Xencor will receive a payment from Alexion.
Xencor Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and antibody therapeutics. Powered by its proprietary XmAb protein engineering platform, Xencor designs drug candidates optimized for enhanced efficacy and safety profiles to treat patients with cancer, asthma, allergic diseases, and autoimmune conditions. The company maintains a broad pipeline, with more than 20 programs in clinical testing and numerous others in preclinical development. Notably, three XmAb medicines are currently marketed by strategic partners, enabling milestone payments, royalties, and collaborative advancements. Xencor focuses on expanding the therapeutic potential of antibodies through innovative protein engineering from the ground up, addressing severe diseases where conventional treatments fall short. Founded in 1997 and headquartered in Monrovia, California, Xencor plays a key role in the biotechnology sector by advancing next-generation biologics for unmet medical needs.
CEO Dr. Bassil I. Dahiyat Ph.D. · 260 employees · United States · https://www.xencor.com